Compare Sanofi SA (SNY) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Tyson Foods, Inc. — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Tyson Foods, Inc. trades at $53.43 (market cap $18.41B). The key difference: Sanofi SA is far larger — about 5.2× Tyson Foods, Inc.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Tyson Foods, Inc. for 76 Days on average.
| SNY | TSN | |
|---|---|---|
Market Cap | $95.18B | $18.41B |
Volume | 2,995,646 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $52.34 | $68.75 |
52-Week Low | $39.51 | $50.47 |
Typical Hold Time | 94 Days | 76 Days |
Enterprise Value | $114.48B | $25.68B |
Dividend Yield | 6.01% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Tyson Foods (TSN) trades at $52.34, up 1.24% on the day, with a bullish technical signal but mixed earnings history including a recent Q4 2025 miss. Valuation ratios like P/S of 0.33 appear attractive, but thin net margins of 1.03% and ongoing cash flow challenges highlight operational pressures. Recent news includes a lowered fiscal 2026 outlook and a securities investigation, adding uncertainty despite insider buying and institutional interest.
The stock offers a potential 25% upside to the consensus price target of $65.40, supported by a majority analyst buy rating. However, risks are elevated from beef segment losses, negative cash flows, and legal scrutiny. Investor sentiment is cautious amid guidance cuts, making earnings execution critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
